Italy’s life‑science sector gains clinical strength and venture capital but still trails Europe’s leaders

In a recent episode of BioSpace’s Denatured podcast, host Jennifer C. Smith‑Parker talks with Diana Saraceni of Panakès Partners and Fabrizio Calisti of Angelini Ventures about Italy’s life‑science ecosystem.

The guests note that over the past ten years Italy has built stronger technology‑transfer capabilities and attracted more venture‑capital funding, giving local biotech firms better access to clinical development resources.

Despite these gains, they say the country still lags behind the United Kingdom, Germany and France in the number of new companies and the scale at which they operate, highlighting remaining gaps in the ecosystem.

The discussion suggests that continued investment in culture and capital will be needed for Italy to reach parity with its European peers.